Linezolid, Levofloxacin, and Vancomycin Against Vancomycin-Tolerant and Fluoroquinolone-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model

Raymond Cha, Pharm.D.; Ronda L. Akins, Pharm.D.; Michael J. Rybak, Pharm.D., M.S., FCCP

Disclosures

Pharmacotherapy. 2003;23(12) 

In This Article

Abstract and Introduction

Study Objective: To compare the pharmacodynamic profiles of linezolid, levofloxacin, and vancomycin against clinical strains of Streptococcus pneumoniae, including vancomycin-tolerant and fluoroquinolone-resistant isolates.
Design: In vitro pharmacodynamic model.
Setting: Biosafety level 2, university research laboratory.
Bacterial Strains: Ciprofloxacin-susceptible (79), ciprofloxacin-resistant (R921), and vancomycin-tolerant (P9802-020) clinical strains of S. pneumoniae.
Intervention: An in vitro pharmacodynamic model was used to simulate standard dosing regimens of linezolid, levofloxacin, and vancomycin against the isolates 79, R921, and P9802-020.
Measurements and Main Results: Bacterial density was profiled over 48 hours. Minimum inhibitory concentrations (MICs) for linezolid, levofloxacin, and vancomycin, respectively, were 1, 1, 0.5 µg/ml for isolate 79; 1, 4, 0.5 µg/ml for R921; and 0.5, 0.5, 0.5 µg/ml for P9802-020. Vancomycin minimum bactericidal concentration (MBC) values varied across large ranges for the tested strains. Linezolid achieved 99.9% kill against 79 and R921 by 24 and 28 hours, respectively. Levofloxacin achieved 99.9% kill against 79 and P9802-020 by 28 and 4 hours, respectively. Vancomycin achieved 99.9% kill against 79 and R921 by 8 and 24 hours, respectively. Levofloxacin did not demonstrate activity against R921 at the 48-hour end point. Minimal kill (< 2 log) at 48 hours was noted for vancomycin and linezolid against P9802-020.
Conclusion: Vancomycin tolerance appeared to be more reliably characterized by persistent viability in time-kill analyses than by MBC:MIC ratios. Vancomycin exhibited bactericidal activity against the non-vancomycin-tolerant strains of S. pneumoniae. Linezolid exhibited both bactericidal and bacteriostatic activity against all three strains tested, whereas levofloxacin demonstrated bactericidal activity against the fluoroquinolone-susceptible isolates. Further investigation of treatment alternatives for infections due to vancomycin-tolerant S. pneumoniae are needed.

Antimicrobial resistance among gram-positive bacteria has become increasingly prevalent and has been paralleled by the occurrence of serious bacteremia, pneumonia, meningitis, and otitis media caused by Streptococcus pneumoniae.[1,2,3,4] The burden of drug-resistant S. pneumoniae has increased by more than 8% to an overall prevalence of about 30% in the United States and Canada.[1,5] Furthermore, pneumococci with reduced susceptibility to fluoroquinolones have been described in Canada, Hong Kong, Spain, and the United States.[3,6,7,8,9] This is a serious challenge due to diminution of potential treatment options and requires a multidisciplinary approach in conjunction with improved clinical strategies to limit further occurrences of multidrug-resistant S. pneumoniae infections.

Adding to this problem is the first report, to our knowledge, of a S. pneumoniae isolate that exhibited tolerance to vancomycin based on in vitro viability analyses.[10] That report soon was followed by the first characterization of a recrudescent meningitis infection due to S. pneumoniae that showed tolerance to vancomycin based on clinical presentation and was confirmed by in vitro time-kill analyses.[11] The potential for further identification of infections due to vancomycin-tolerant S. pneumoniae substantiates the need for evaluation of treatment options. To date, published data on assessment of antimicrobials against this pathogen are limited to vancomycin in time-kill analyses and observational data from one clinical report.[10,11]

Potential alternatives consist of two classes of antimicrobials that exhibit non-cell-wall-mediated mechanisms of action: oxazolidinones and fluoroquinolones. Linezolid, a new synthetic agent belonging to the oxazolidinone class of antibiotic, has broad antimicrobial activity against a variety of gram-positive bacteria, including resistant organisms. The agent acts like no other at the 50S ribosomal target site responsible for initiation of protein synthesis and has demonstrated no cross-resistance to other antimicrobials thus far.[12,13] The spectrum of activity, mechanism of activity, and favorable pharmacokinetics of linezolid establish it as a potential agent in the treatment of resistant gram-positive infections. Extended-spectrum fluoroquinolones possess enhanced gram-positive coverage and have increased dramatically in use as a result of their distinctively characteristic mechanism of activity (inhibition of DNA gyrase and/or topoisomerase IV), antimicrobial spectrum, and favorable pharmacokinetic profiles.[14,15] We chose to characterize the activity of linezolid and levofloxacin compared with that of vancomycin against vancomycin-tolerant and -sensitive clinical strains of S. pneumoniae in an in vitro pharmacodynamic model.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....